vs
Side-by-side financial comparison of GRAHAM CORP (GHM) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.
Viridian Therapeutics, Inc.\DE is the larger business by last-quarter revenue ($70.6M vs $56.7M, roughly 1.2× GRAHAM CORP). GRAHAM CORP runs the higher net margin — 5.0% vs -49.0%, a 54.0% gap on every dollar of revenue. On growth, Viridian Therapeutics, Inc.\DE posted the faster year-over-year revenue change (81958.1% vs 20.5%). GRAHAM CORP produced more free cash flow last quarter ($2.4M vs $-84.7M).
Graham Holdings Company is a diversified American conglomerate holding company. Headquartered in Arlington County, Virginia, and incorporated in Delaware, it was formerly the owner of The Washington Post newspaper and Newsweek magazine.
Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.
GHM vs VRDN — Head-to-Head
Income Statement — Q3 FY2026 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $56.7M | $70.6M |
| Net Profit | $2.8M | $-34.6M |
| Gross Margin | 23.8% | — |
| Operating Margin | 5.5% | -56.7% |
| Net Margin | 5.0% | -49.0% |
| Revenue YoY | 20.5% | 81958.1% |
| Net Profit YoY | 79.2% | 54.9% |
| EPS (diluted) | $0.25 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $56.7M | — | ||
| Q3 25 | $66.0M | $70.6M | ||
| Q2 25 | $55.5M | — | ||
| Q1 25 | $59.3M | — | ||
| Q4 24 | $47.0M | — | ||
| Q3 24 | $53.6M | — | ||
| Q2 24 | $50.0M | — | ||
| Q1 24 | $49.1M | — |
| Q4 25 | $2.8M | — | ||
| Q3 25 | $3.1M | $-34.6M | ||
| Q2 25 | $4.6M | — | ||
| Q1 25 | $4.4M | — | ||
| Q4 24 | $1.6M | — | ||
| Q3 24 | $3.3M | — | ||
| Q2 24 | $3.0M | — | ||
| Q1 24 | $1.3M | — |
| Q4 25 | 23.8% | — | ||
| Q3 25 | 21.7% | — | ||
| Q2 25 | 26.5% | — | ||
| Q1 25 | 27.0% | — | ||
| Q4 24 | 24.8% | — | ||
| Q3 24 | 23.9% | — | ||
| Q2 24 | 24.8% | — | ||
| Q1 24 | 25.9% | — |
| Q4 25 | 5.5% | — | ||
| Q3 25 | 6.5% | -56.7% | ||
| Q2 25 | 8.9% | — | ||
| Q1 25 | 9.3% | — | ||
| Q4 24 | 4.7% | — | ||
| Q3 24 | 7.9% | — | ||
| Q2 24 | 6.5% | — | ||
| Q1 24 | 3.1% | — |
| Q4 25 | 5.0% | — | ||
| Q3 25 | 4.7% | -49.0% | ||
| Q2 25 | 8.3% | — | ||
| Q1 25 | 7.4% | — | ||
| Q4 24 | 3.4% | — | ||
| Q3 24 | 6.1% | — | ||
| Q2 24 | 5.9% | — | ||
| Q1 24 | 2.7% | — |
| Q4 25 | $0.25 | — | ||
| Q3 25 | $0.28 | — | ||
| Q2 25 | $0.42 | — | ||
| Q1 25 | $0.40 | — | ||
| Q4 24 | $0.14 | — | ||
| Q3 24 | $0.30 | — | ||
| Q2 24 | $0.27 | — | ||
| Q1 24 | $0.11 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $22.3M | $490.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $131.3M | $503.0M |
| Total Assets | $292.9M | $577.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $22.3M | — | ||
| Q3 25 | $20.6M | $490.9M | ||
| Q2 25 | $10.8M | — | ||
| Q1 25 | $21.6M | — | ||
| Q4 24 | $30.0M | — | ||
| Q3 24 | $32.3M | — | ||
| Q2 24 | $21.6M | — | ||
| Q1 24 | $16.9M | — |
| Q4 25 | $131.3M | — | ||
| Q3 25 | $127.6M | $503.0M | ||
| Q2 25 | $123.4M | — | ||
| Q1 25 | $119.6M | — | ||
| Q4 24 | $114.4M | — | ||
| Q3 24 | $112.5M | — | ||
| Q2 24 | $108.2M | — | ||
| Q1 24 | $105.6M | — |
| Q4 25 | $292.9M | — | ||
| Q3 25 | $287.0M | $577.1M | ||
| Q2 25 | $252.3M | — | ||
| Q1 25 | $264.1M | — | ||
| Q4 24 | $264.3M | — | ||
| Q3 24 | $249.5M | — | ||
| Q2 24 | $244.2M | — | ||
| Q1 24 | $233.9M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $4.8M | $-84.6M |
| Free Cash FlowOCF − Capex | $2.4M | $-84.7M |
| FCF MarginFCF / Revenue | 4.3% | -120.1% |
| Capex IntensityCapex / Revenue | 4.1% | 0.2% |
| Cash ConversionOCF / Net Profit | 1.67× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-6.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $4.8M | — | ||
| Q3 25 | $13.6M | $-84.6M | ||
| Q2 25 | $-2.3M | — | ||
| Q1 25 | $-3.6M | — | ||
| Q4 24 | $5.2M | — | ||
| Q3 24 | $13.9M | — | ||
| Q2 24 | $8.7M | — | ||
| Q1 24 | $8.6M | — |
| Q4 25 | $2.4M | — | ||
| Q3 25 | $9.4M | $-84.7M | ||
| Q2 25 | $-9.3M | — | ||
| Q1 25 | $-8.7M | — | ||
| Q4 24 | $-2.1M | — | ||
| Q3 24 | $10.4M | — | ||
| Q2 24 | $5.7M | — | ||
| Q1 24 | $4.6M | — |
| Q4 25 | 4.3% | — | ||
| Q3 25 | 14.3% | -120.1% | ||
| Q2 25 | -16.7% | — | ||
| Q1 25 | -14.7% | — | ||
| Q4 24 | -4.5% | — | ||
| Q3 24 | 19.5% | — | ||
| Q2 24 | 11.5% | — | ||
| Q1 24 | 9.4% | — |
| Q4 25 | 4.1% | — | ||
| Q3 25 | 6.3% | 0.2% | ||
| Q2 25 | 12.6% | — | ||
| Q1 25 | 8.7% | — | ||
| Q4 24 | 15.6% | — | ||
| Q3 24 | 6.5% | — | ||
| Q2 24 | 6.0% | — | ||
| Q1 24 | 8.2% | — |
| Q4 25 | 1.67× | — | ||
| Q3 25 | 4.40× | — | ||
| Q2 25 | -0.49× | — | ||
| Q1 25 | -0.81× | — | ||
| Q4 24 | 3.29× | — | ||
| Q3 24 | 4.25× | — | ||
| Q2 24 | 2.94× | — | ||
| Q1 24 | 6.45× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GHM
| Defense | $35.3M | 62% |
| Energy And Process | $18.3M | 32% |
| Space | $3.1M | 6% |
VRDN
Segment breakdown not available.
